Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing agreement with the Trump ...

Hetlioz (tasimelteon) has been approved in the US for a few years to treat sleep disorders affecting people who are blind or ...

In the same week that Servier announced its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has ...

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...

The Cambridge, Massachusetts-based company – known as FogPharma until a rebrand in 2024 – needs cash for pivotal trials of ...

Overall, it found that patients could lose up to a fifth of their body weight using the injectable GLP-1s, but put it back on ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

For over 60 years, the search for an effective pharmacologic treatment for refractory or unexplained chronic cough has been ...

The ISPOR Glasgow panel conveyed a constructive, forward looking mood: JCA can work – and work better over time – if ...

Bayer's agrochemicals unit Monsanto has filed lawsuits in the US against the manufacturers of mRNA-based COVID-19 vaccines, ...

Ribo's IPO is aiming to raise around HKD 1.59 billion (around $205 million) through the sale of 27.5 million shares at HKD 57 ...

A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...